RxDoctor Payments Data

Svetlana Tikhomirova, MD

Internal Medicine · Danbury, CTNPI 1689631467

Payments from drug & device makers

$2,157in general payments, 2019–2025

Across 132 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$409
  • Pfizer$217
  • Amgen$176
  • AstraZeneca$160
  • Astellas Pharma US Inc$157
  • Merck$156
  • plus $881 from 16 others

What the payments were for

  • Food & beverage$2,157100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,157 in reported general payments places this provider in the 80th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$240,758
Medicare patients
424
Services billed
4,882

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala31$133,160
OzempicSemaglutide73$93,084
EliquisApixaban31$50,077
JanuviaSitagliptin Phosphate29$47,677
JardianceEmpagliflozin36$42,226
RybelsusSemaglutide23$28,418
SynthroidLevothyroxine Sodium119$11,307
Breo ElliptaFluticasone/Vilanterol13$10,231
Ezetimibe123$6,777
Atorvastatin Calcium531$5,651
Levothyroxine Sodium449$5,070
Rosuvastatin Calcium332$4,672
Duloxetine Hcl31$3,465
Losartan Potassium268$2,649
Amlodipine Besylate330$2,597

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$97$133,16031 claims
Novo NordiskOzempic, Rybelsus$409$121,50296 claims
PfizerEliquis$217$50,07731 claims
MerckJanuvia$156$47,67729 claims
Boehringer IngelheimJardiance$92$42,22636 claims
AbbVieSynthroid$36$11,307119 claims
GSKBreo Ellipta$67$10,23113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Danbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →